Osama Amro, MD
Nephrology · Seattle, WANPI 1154642643
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $281,197 of the $395,037 with a category attached, or 71.2%. Otsuka America Pharmaceutical, Inc. accounts for 83.0% of it on its own, with 13 other manufacturers making up the rest. Among nephrology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $751.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$328K
- Novartis$27K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$17K
- Travere Therapeutics, Inc.$12K
- Sanofi$4K
- Aurinia Pharma U.S., Inc.$3K
- plus $4K from 8 others
Across 38 payments — averaging $26,345 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$767K
- Biogen$51K
- AstraZeneca$50K
- Aurinia Pharma U.S., Inc.$46K
- Vertex$37K
- AbbVie$31K
- plus $20K from 1 others
What the payments were for
- Consulting fees$73,77919%
- Speaking & faculty fees$281,19771%
- Travel & lodging$32,0488%
- Food & beverage$7,6962%
- Education$3170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 448 | $328,004 |
| Novartis | 20 | $26,557 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $16,830 |
| Travere Therapeutics, Inc. | 24 | $12,489 |
| Sanofi | 1 | $3,923 |
| Aurinia Pharma U.S., Inc. | 4 | $2,869 |
| Bayer | 3 | $2,633 |
| AstraZeneca(2 entities) | 6 | $613 |
| Vertex | 1 | $517 |
| Baxter Healthcare | 2 | $165 |
| Vifor Pharma, Inc. | 2 | $159 |
| Mallinckrodt Hospital Products Inc. | 1 | $138 |
| Vantive US Healthcare LLC | 1 | $122 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$395,037 in reported general payments places this provider in the 95th percentile of 237 nephrology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 37 | $726,243 |
| FilspariSparsentan | 24 | $285,414 |
| FarxigaDapagliflozin Propanediol | 229 | $261,521 |
| VelphoroSucroferric Oxyhydroxide | 23 | $112,303 |
| JardianceEmpagliflozin | 56 | $81,726 |
| KerendiaFinerenone | 61 | $76,096 |
| VeltassaPatiromer Calcium Sorbitex | 29 | $34,530 |
| LokelmaSodium Zirconium Cyclosilicate | 38 | $32,984 |
| Sevelamer Carbonate | 43 | $9,828 |
| DapagliflozinDapagliflozin Propanediol | 15 | $8,168 |
| Calcium Acetate | 52 | $5,919 |
| Calcitriol | 282 | $4,852 |
| Potassium Citrate ErPotassium Citrate | 35 | $2,461 |
| Losartan Potassium | 219 | $1,914 |
| Hydralazine Hcl | 118 | $1,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $328,004 | $726,24337 claims |
| AstraZenecaFarxiga, Lokelma | $613 | $294,505267 claims |
| Travere Therapeutics, Inc.Filspari | $12,489 | $285,41424 claims |
| BayerKerendia | $2,633 | $76,09661 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 nephrology providers in Washington.
Other nephrology in Seattle
- Ian de BoerSeattle$117K
- Nicolae LecaSeattle$101K
- Syeda AhmadSeattle$68K
- Stuart ShanklandSeattle$10K
- Anne PesensonSeattle$10K
- Lisa NakamotoSeattle$9K
- Nisha BansalSeattle$8K
- Michael TekesteSeattle$6K
- Sarah SanghaviSeattle$4K
- Bryan KestenbaumSeattle$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.